| Rank |
Status |
Study |
| 1 |
Recruiting
|
Adjunctive Clindamycin for Cellulitis: Clinical Trial Comparing Flucloxacillin With or Without Clindamycin for the Treatment of Limb Cellulitis (C4C Trial).
| Condition: |
Cellulitis |
| Interventions: |
Drug: Flucloxacillin and Clindamycin; Drug: Flucloxacillin and placebo |
| Outcome Measures: |
Improvement based on a composite of systemic and local features; Decrease in pain; Quality of life; Physiological recovery |
|
| 2 |
Recruiting
|
Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
| Conditions: |
Abnormal Vaginal Flora; Clindamycin Vs Metronidazole; High Risk Pregnancies for Preterm Labor |
| Interventions: |
Drug: Clindamycin; Drug: Metronidazole |
| Outcome Measures: |
To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora; The prevalence of adverse effects; The prevalence of late abortions and preterm deliveries; Assessing the correlation between Nugent score , physical examination and Ph indicators |
|
| 3 |
Recruiting
|
Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
| Conditions: |
Bacterial Infections; Obesity |
| Intervention: |
Drug: Clindamycin |
| Outcome Measures: |
Clearance (Cl); Volume of distribution (Vd); Area under the curve (AUCtau); Oral apparent clearance (Cl/F); Oral apparent volume of distribution (V/F); Number of Adverse Events |
|
| 4 |
Unknown †
|
A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
| Condition: |
Acne Vulgaris |
| Interventions: |
Drug: Clindamycin phosphate 1.2%/tretinoin 0.025% gel alone; Drug: Clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths |
| Outcome Measures: |
Change in PGA scores of patients using combination Clindamycin phosphate 1.2%/tretinoin 0.025% gel with or without benzoyl peroxide 6% foaming cloths for facial acne; Change in Postinflammatory hyperpigmentation score at each study visit and from baseline to final visit.; Total number of adverse events.; Change in Subject Self Assessment Scoring Scale; Change in Acne-Specific Quality of Life Questionnaire (Acne-QoL) |
|
| 5 |
Recruiting
|
Clindamycin to Reduce Preterm Birth in a Low Resource Setting
| Conditions: |
Pregnancy; Prematurity; Preterm Birth; Bacterial Vaginosis |
| Interventions: |
Drug: Clindamycin; Drug: Placebo |
| Outcome Measures: |
Preterm birth prior to 37 weeks; Preterm birth prior to 34 weeks; Late Miscarriage; Low Birth weight; Very Low birth Weight; Neonatal complications through 42 days after delivery; Maternal complications through 42 days postpartum; The utility of vaginal pH tests for identification of women at elevated risk for preterm delivery |
|
| 6 |
Recruiting
|
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
| Conditions: |
Skin Diseases, Bacterial; Abscess |
| Interventions: |
Biological: Linezolid; Biological: Clindamycin |
| Outcome Measures: |
The presence of Staphylococcus aureus after treatment with linezolid versus Clindamycin; Clinical response of skin infections to treatment; The type of of Staphylococcus aureus present at the diagnosis will be compared to the type of Staphylococcus aureus present after treatment |
|
| 7 |
Recruiting
|
Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
| Condition: |
Acne Vulgaris |
| Interventions: |
Drug: Clindamycin + BPO; Drug: Azelaic acid |
| Outcome Measures: |
Change from Baseline of inflammatory lesion counts at Week 4; Change from Baseline of lesion counts; Change from Baseline of lesions by Investigator's Static Global Assessment (ISGA); Time to 50% reduction in total lesion count; Change from Baseline of local tolerability as assessed by investigator; Subject's global change assessment (SGCA) of skin; Change from Baseline of local tolerability as assessed by subject; Subject satisfaction score at Week 12; Measured adherence to study medication at Week 12; Quality of Life Assessments; Number of treatment related adverse events (AEs) and serious adverse events (SAEs) |
|
| 8 |
Unknown †
|
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
| Condition: |
Malaria |
| Intervention: |
Drug: Fosmidomycin and Clindamycin |
| Outcome Measures: |
Cure rate; cure rate |
|
| 9 |
Recruiting
|
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
| Condition: |
Acne Vulgaris |
| Interventions: |
Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel; Drug: DUAC® Gel; Drug: Placebo |
| Outcome Measures: |
Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions.; Mean percent change from baseline to week 11 in the non-inflammatory lesion count; Proportion of subjects with a clinical response of "success" at week 11 |
|
| 10 |
Unknown †
|
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
| Conditions: |
Candidiasis; Bacterial Vaginosis |
| Interventions: |
Drug: Clindamycin 100mg and Ketoconazole 400mg; Drug: Tetracycline 100mg and Amphotericin B 50mg |
| Outcome Measures: |
Efficacy based on cure rate evaluated by clinical and laboratory criteria.; Tolerability based on adverse events reports and patient's information; Safety based on adverse events reports and laboratory criterion |
|
| 11 |
Recruiting
|
Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage
| Condition: |
Peritonsillar Abscess |
| Interventions: |
Drug: Clavulin; Drug: Randomization to Placebo; Drug: Clindamycin |
| Outcome Measure: |
Re-accumulation of the patient's peri-tonsillar abscess |
|
| 12 |
Unknown †
|
Treatment of Chorioamnionitis After Delivery
| Condition: |
Chorioamnionitis |
| Interventions: |
Drug: saline; Drug: ampicillin gentamicin; Drug: Ampicillin gentamicin Clindamycin; Drug: ampicillin gentamicin Clindamycin |
| Outcome Measure: |
To determine the courses of antibiotics needed after vaginal delivery and after cesareans in pregnancies complicated by chorioamnionitis. |
|
| 13 |
Recruiting
|
Antibiotic Safety (SCAMP)
| Condition: |
Complicated Intra Abdominal Infections |
| Interventions: |
Drug: ampicillin and metronidazole and gentamicin; Drug: ampicillin and gentamicin and Clindamycin; Drug: gentamicin and Piperacillin- tazobactam; Drug: standard of care antibiotics and metronidazole |
| Outcome Measures: |
Death; Number of participants with therapeutic success at Day 30 and Day 90 |
|
| 14 |
Unknown †
|
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage
| Conditions: |
Skin and Soft Tissue Abscess; Methicillin-resistant Staphylococcus Aureus (MRSA) Infection |
| Intervention: |
Drug: Oral Clindamycin |
| Outcome Measures: |
The primary objective is to measure clinical resolution of skin abscess at routine follow-up visit 10-14 days post operation.; Secondary outcomes measured include incidence of additional skin and soft tissue infections in patient and in household contacts as determined by healthcare provider. Compliance to antibiotic regime will also be assessed at this time. |
|
| 15 |
Not yet recruiting
|
Orthognathic Surgery and Postoperative Antibiotic Use
| Condition: |
Dentofacial Deformity |
| Intervention: |
Drug: Cefazolin, Cephalexin, Clindamycin |
| Outcome Measures: |
Rate of infection; Side effect from antibiotic use |
|
| 16 |
Not yet recruiting
|
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
| Condition: |
Endometritis |
| Interventions: |
Drug: Antibiotic prophylaxis; Drug: Ampicillin; Drug: Gentamycin; Drug: Clindamycin |
| Outcome Measures: |
Endometritis rate; Puerperal fever |
|
| 17 |
Recruiting
|
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
| Condition: |
Staphylococcal Infection |
| Interventions: |
Drug: Clindamycin; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Placebo |
| Outcome Measures: |
Clinical cure, defined as absence of clinical failure.; Efficacy outcome: clinical cure of recurrences or relapses of SSTI.; Safety outcomes: adverse events; and adverse events that are treatment limiting. |
|
| 18 |
Recruiting
|
PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
| Condition: |
Systemic Infection |
| Intervention: |
Drug: Antibiotic |
| Outcome Measures: |
Pharmacokinetic concentrations in plasma will be measured at a central lab using a validated bioanalytical assay. Plasma samples will be drawn according to specific schedules for each drug; Safety review will be performed through monitoring of adverse events each day that the infant is on study |
|
| 19 |
Recruiting
|
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
| Conditions: |
Colorectal Cancer; Head and Neck Cancer |
| Interventions: |
Drug: Doxycycline; Drug: Hydrocortisone 1% cream; Other: Sunscreen; Other: Moisturizer; Drug: Clindamycin; Drug: Medrol-dose pack (Steroid) |
| Outcome Measures: |
Incidence of Rash; Quality of Life (QOL); Adherence to treatment regimen; Progression Free Survival |
|
| 20 |
Recruiting
|
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus
| Condition: |
Bacteremia |
| Interventions: |
Drug: Daptomycin; Drug: Comparator (Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin) |
| Outcome Measures: |
Safety of daptomycin measured by the incidence of treatment-emergent adverse events, vital signs, echocardiogram (if performed) and clinical laboratory tests, use of concomitant medications,physical and neurological exam results.; Efficacy of daptomycin will be based on Investigator's assessment of clinical response (cure, improved, failure or non-evaluable) at the Test of Cure (TOC) visit. |
|
